Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Why Intellia Therapeutics Stock Is Skyrocketing Today
11:09am, Monday, 28'th Jun 2021
The company reported promising interim trial results for its CRISPR gene-editing candidate.
Biotech Blasts to Record Highs After Upbeat Trial Data
10:43am, Monday, 28'th Jun 2021
The shares of biotechnology name Intellia Therapeutics Inc (NASDAQ:NTLA) are soaring this morning, up 48% to trade at $131.92 at last check -- earlier hitting a record high of $144.39 -- after positiv
What Will the Stock Market Do Today? 3 Big Stories to Watch.
10:36am, Monday, 28'th Jun 2021
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
GameStop rating suspended by Bird, Virgin Galactic soars on FAA approval and Intellia pops
10:34am, Monday, 28'th Jun 2021
Yahoo Finance's Brian Sozzi and Myles Udland discuss GameStop, Virgin Galactic and Intella Therapeutics. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-O
Here's why Intellia Therapeutics stock gained 55% on Monday
09:59am, Monday, 28'th Jun 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) said on Saturday its clinical trial that used Crispr technology to treat a genetic disorder inside the human body showed positive results. The biotech company
Why Intellia Therapeutics Stock Is Soaring Today
08:49am, Monday, 28'th Jun 2021
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. What Happened: Intellia and Regeneron
First In-Vivo Gene Editing Data Look Good for Intellia
08:39am, Monday, 28'th Jun 2021
At a meeting of neurologists Saturday morning, researchers said that the first patients to get Intellia's gene-editing treatment showed improvements in their inherited liver disorder.
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
06:09am, Monday, 28'th Jun 2021
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which is being developed
NTLA Stock Price Increases Over 30% Pre-Market: Why It Happened
04:44am, Monday, 28'th Jun 2021
The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) increased by over 30% pre-market. This is why it happened.
First In-Vivo Gene Editing Data Look Good for Intellia
11:15am, Saturday, 26'th Jun 2021
At a meeting of neurologists Saturday morning, researchers said that the first patients to get Intellia's gene-editing treatment showed improvements in their inherited liver disorder.
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
07:30am, Thursday, 24'th Jun 2021
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technol
3 Biotech Stocks With Big Catalysts in June
06:41am, Tuesday, 22'nd Jun 2021
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.
CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced that a late-breaking abstract featuring interim Phase 1 clinical data from NTLA-2001, th
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
06:40am, Friday, 07'th May 2021
One company is setting itself apart in a crowded field.
Buying This Beaten-Down ETF Could Make You a Fortune Over the Next 10 Years
05:52am, Friday, 07'th May 2021
It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.
